SI-BONE, Inc. Shows Impressive Revenue Growth in Q3
In a notable development, SI-BONE, Inc. has reported its financial results for the third quarter of 2025, signaling robust growth in revenue and operating performance. The company has successfully delivered approximately 21% growth in worldwide revenue, achieving $48.7 million, compared to $40.3 million in the same period last year. This substantial growth is a testament to the strong demand for SI-BONE's innovative surgical solutions aimed at treating sacropelvic disorders.
Third Quarter Financial Highlights
The financial highlights from the third quarter 2025 provide a clear view of SI-BONE's strong performance.
Expanding Revenue Streams
U.S. revenue for this quarter reached $46.4 million, indicating a year-over-year increase of 21.2%. This surge in revenue can be attributed to the heightened procedure demand in the U.S. market. Furthermore, the company's gross margin improved to 79.8%, reflecting an increase of 75 basis points from the prior year.
Enhanced Profitability
SI-BONE reported a net loss of $4.6 million, which represents a significant improvement of 30.6% from the prior year, highlighting the company’s efficiency measures and operational strategies. Additionally, the firm recorded an adjusted EBITDA of positive $2.3 million, which shows a considerable rebound from an adjusted EBITDA loss in the previous year.
Operational Achievements in Q3
SI-BONE's operational highlights further underscore its position in the market. The company reported that it has engaged 1,530 active U.S. physicians, marking a remarkable growth of 27%. Moreover, the trailing 12-month average revenue per territory increased to $2.1 million, up by 16% compared to the previous year.
Innovative Technology Introduction
Introducing the New Technology Add-on Payment (NTAP) for the iFuse TORQ TNT procedure, SI-BONE is set to benefit significantly as this new payment structure becomes effective. This strategic move is expected to improve procedure adoption and further enhance revenue streams.
Future Guidance Looks Bright
Looking ahead, SI-BONE has revised its financial outlook for 2025, with worldwide revenue expected to be between $198 million and $200 million. This represents an estimated year-over-year growth of approximately 18% to 20%. The company projects a gross margin of around 79.5% for the full year, which indicates a healthy profit potential moving forward.
Continuous Innovation and Growth
SI-BONE's Chief Executive Officer, Laura Francis, stated that the sustained procedure volume growth and the increasing number of engaged physicians reflect robust demand for the company's differentiated platform. As the company continues to innovate and expand its pipeline of novel technologies, it is well-positioned for consistent, profitable growth.
Conclusion: A Strong Position in the Market
With its impressive financial performance and optimism about the future, SI-BONE, Inc. is carving out a notable presence in the medical device sector. Investors and stakeholders are encouraged by the company's ability to navigate challenges and capitalize on emerging opportunities in the sacropelvic disorders market.
Frequently Asked Questions
What were SI-BONE's revenues for Q3 2025?
SI-BONE reported a worldwide revenue of $48.7 million for the third quarter of 2025.
How much did U.S. revenue grow?
The U.S. revenue increased by 21.2%, reaching $46.4 million.
What is the expected revenue growth for SI-BONE in 2025?
SI-BONE has revised its revenue guidance for 2025, estimating it will be between $198 million and $200 million.
What is the adjusted EBITDA for Q3 2025?
The adjusted EBITDA for SI-BONE in Q3 2025 was positive $2.3 million.
What innovative technology was recently introduced by SI-BONE?
SI-BONE introduced the New Technology Add-on Payment for the iFuse TORQ TNT procedure.
